Slideshow

Best of MS: AAN 2017

The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.

Chosen studies presented at AAN 2017 included an evaluation of cortical lesions in MS; 6-year outcomes of treatment with alemtuzumab in RRMS patients; an investigation of a possible link between viral infections, vitamin D deficiency, and pediatric-onset MS; and a look at the possibility of fatigue and lower limb problems predicting progression from RRMS to SPMS. 

Related Videos
Joseph Kuchling, MD  (Credit: Cognitive Neurology Lab)
 Xavier Montalban, MD, PhD
Marcello Moccia, MD, PhD
Mikael Cohen, MD
Robert J. Fox, MD; Andreas Muehler, MD, MBA
Wallace Brownlee, MBChB, PhD, FRACP
Tom Fuchs, MD, PhD
Robert J. Fox, MD
Shamik Bhattacharyya, MD
Valentin Krüger, MD
© 2024 MJH Life Sciences

All rights reserved.